Kit-63 200 mg+200 mcg (Tablet)
(1+4) tablet kit: ৳ 300.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Mifepristone misoprostol |
| Company | General pharmaceuticals ltd |
Indications
- Early Menstrual Regulation (MR)
- Termination of pregnancy up to 9 weeks
- Gestation of 63 days
Composition
- Each box contains 2 blister strips
- 1 tablet of Mifepristone INN 200 mg
- 4 tablets of Misoprostol USP 200 microgram each
Pharmacology
- Mifepristone is a synthetic steroid with anti-progestational activity
- Misoprostol is a synthetic analogue of prostaglandin E1
- Mifepristone sensitizes the myometrium to contraction-inducing activity of prostaglandins
- Misoprostol causes myometrial contraction by interacting with specific receptors
Dosage & Administration
- Mifepristone administration on Day 1
- Misoprostol administration 24-48 hours after ingesting Mifepristone tablet
- Post-treatment examination on Day 10 to 14
Interaction
- Potential inhibition of Mifepristone metabolism by Ketoconazole, Itraconazole, Erythromycin, & grapefruit juice
Contraindications
- History of allergy or known hypersensitivity to Mifepristone or Misoprostol
- Confirmed or suspected ectopic pregnancy
- Undiagnosed adnexal mass
- IUD in place
- Chronic adrenal failure
- Haemorrhagic disorders or concurrent anticoagulant therapy
- Inherited porphyria
Side Effects
- Nausea
- Vomiting
- Diarrhoea
- Pelvic pain
- Fainting
- Headache
- Dizziness
- Asthenia
- Diarrhea
- Abdominal pain
- Flatulence
- Dyspepsia
- Headache
- Vomiting
- Constipation
- Shivering
- Hyperthermia
- Severe vaginal bleeding
- Shock
- Pelvic pain
- Uterine rupture
- Pain due to uterine contractions
Pregnancy & Lactation
- Mifepristone is indicated for Menstrual Regulation (MR) through 63 days pregnancy
- Surgical termination is recommended for treatment failures
- Unknown excretion of Mifepristone through human milk
- Potential excretion of Misoprostol acid could cause diarrhea in nursing infants
Precautions & Warnings
- Combination of Mifepristone & Misoprostol should not be given to anyone else
- Intra Uterine Device [IUD] should be removed before treatment with Mifepristone
- Surgical termination is recommended for treatment failures
Use in Special Populations
- Patients with hepatic disease should receive a decreased dose of Misoprostol
- No routine dosage adjustment recommended for older patients or patients with renal impairment
Overdose Effects
- No serious adverse reactions reported in tolerance studies for Mifepristone
- Clinical signs of Misoprostol overdose include sedation, tremor, convulsions, dyspnea, abdominal pain, and diarrhea
Therapeutic Class
- Drugs acting on the Uterus
- Prostaglandin analogues
Storage Conditions
- Store in a cool and dry place
- Protected from light